Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Health Catalyst's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Health Catalyst's regulatory disclosures and financial reporting.
Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc. (HCAT), reported a sale of 3,663 shares of the issuer's common stock on 09/02/2025 at a price of $3.3627 per share. The filing states this sale was a mandatory "sell to cover" to satisfy tax-withholding obligations arising from the vesting of restricted stock units and not a discretionary trade. After the transaction, the reporting person beneficially owned 198,367 shares. The Form 4 was signed by Benjamin Landry as attorney-in-fact on 09/04/2025. The report documents an insider compliance action rather than an open-market decision.
Burton D. Burton, Chief Executive Officer and Director of Health Catalyst, Inc. (HCAT), reported a non-discretionary sell-to-cover transaction on 09/02/2025. The filing shows 8,335 shares were sold at $3.3627 per share to satisfy tax withholding obligations arising from vested restricted stock units; this was a mandatory sale under the issuer's equity plan rather than a voluntary trade. After the transaction the reporting person beneficially owns 1,448,814 shares. No derivative securities were reported in this filing and the Form 4 was signed by an attorney-in-fact on 09/04/2025.
Health Catalyst insider sale tied to RSU tax withholding. Chief People Officer Linda Llewelyn reported a sale of 2,854 shares of Health Catalyst, Inc. (HCAT) on 09/02/2025 at $3.3627 per share. The filing states this sale was a mandated "sell-to-cover" to satisfy tax withholding on vested restricted stock units, not a discretionary trade. After the transaction, the reporting person beneficially owned 153,025 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,138 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax withholding from the vesting of restricted stock units. After the transaction, he beneficially owned 147,987 shares. The filing specifies this was a sell-to-cover required under the issuer's equity incentive plan and not a voluntary trade by the reporting person. The Form 4 is signed and dated 09/04/2025.
Health Catalyst, Inc. director Spencer Justin was granted 68,572 restricted stock units (RSUs) on 09/01/2025 under the company's 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock and the award was reported with a $0.00 per-share price, consistent with typical equity awards to directors.
The RSUs vest under the Non-Employee Director Compensation Policy: 33.33% vests on 09/01/2026 and the remaining 66.67% vests in two equal annual installments thereafter. The filing was made by one reporting person and signed by an attorney-in-fact on 09/03/2025.
Health Catalyst, Inc. director reports no share ownership
Spencer Justin, a director of Health Catalyst, Inc. (HCAT), filed an initial ownership report as required for insiders. The filing states in the remarks section that no securities are beneficially owned, and both the non-derivative and derivative ownership tables show no holdings. This indicates that, as of the event date of 09/01/2025, the director reports no direct or indirect ownership of Health Catalyst stock or related derivative securities.
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.
Health Catalyst, Inc. Form 144 summary: This notice reports a proposed sale of 4,578 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 with an aggregate market value of $15,394.44. The filing shows the shares were acquired as restricted stock from Health Catalyst, Inc. on 09/02/2025 as compensation. The filer previously sold 4,747 restricted shares on 06/02/2025 for gross proceeds of $17,254.40. The issuer's outstanding shares are listed as 70,373,625. Some filer identification fields (CIK/CCC and contact details) are not provided in the visible content.
Health Catalyst, Inc. (HCAT) Form 144 summary: This notice reports a proposed sale of 3,138 restricted common shares through Morgan Stanley Smith Barney on 09/02/2025, with an aggregate market value of $10,552.15. The filer acquired these shares as restricted stock on 09/02/2025 as compensation. The filing also discloses two restricted stock sales by the same person in the past three months: 3,255 shares sold on 06/02/2025 for $11,831.27 and 6,057 shares sold on 06/05/2025 for $23,890.63. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Health Catalyst, Inc. (HCAT) filing of Form 144 notifies the market that 2,613 shares of common stock will be offered for sale through Morgan Stanley Smith Barney on 09/02/2025. The filing lists an aggregate market value of $8,786.74 for the shares based on the transaction and shows 70,373,625 shares outstanding for the issuer.
The shares were acquired the same day, 09/02/2025, as restricted stock from Health Catalyst and are identified as compensation. The filer discloses a prior restricted-stock sale of 2,712 shares on 06/02/2025 yielding gross proceeds of $9,857.58. By signing, the person attests they are unaware of undisclosed material adverse information about the issuer.